TO: ALL SWOG MEMBER, CCOP AND AFFILIATE MEDICAL ONCOLOGISTS FROM: SWOG Operations Office RE: IND Safety Reports for IMC-A12 MEMORANDUM

[1]  C. Higano,et al.  A phase II study evaluating the efficacy and safety of single agent IMC A12, a monoclonal antibody (MAb), against the insulin-like growth factor-1 receptor (IGF-IR), as monotherapy in patients with metastastic, asymptomatic castration-resistant prostate cancer (CRPC). , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  Daniel B. Martin,et al.  Circulating microRNAs as stable blood-based markers for cancer detection , 2008, Proceedings of the National Academy of Sciences.

[3]  Cicek Gercel-Taylor,et al.  MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. , 2008, Gynecologic oncology.

[4]  P. Nelson,et al.  An Antibody Targeting the Type I Insulin-like Growth Factor Receptor Enhances the Castration-Induced Response in Androgen-Dependent Prostate Cancer , 2007, Clinical Cancer Research.

[5]  C. Higano,et al.  A phase I study of the recombinant human IgG1 anti-IGF-IR monoclonal antibody (Mab) IMC-A12, administered on a weekly basis to patients with advanced solid tumors: Interim analysis , 2007 .

[6]  J. Lötvall,et al.  Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells , 2007, Nature Cell Biology.

[7]  P. Nelson,et al.  Combined In vivo Effect of A12, a Type 1 Insulin-Like Growth Factor Receptor Antibody, and Docetaxel against Prostate Cancer Tumors , 2006, Clinical Cancer Research.

[8]  P. Nelson,et al.  Interaction of IGF signaling and the androgen receptor in prostate cancer progression , 2006, Journal of cellular biochemistry.

[9]  C. Tangen,et al.  Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162). , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  M. Kawada,et al.  Insulin-like Growth Factor I Secreted from Prostate Stromal Cells Mediates Tumor-Stromal Cell Interactions of Prostate Cancer , 2006 .

[11]  M. Motta,et al.  Insulin-like growth factor-I promotes migration in human androgen-independent prostate cancer cells via the alphavbeta3 integrin and PI3-K/Akt signaling. , 2006, International journal of oncology.

[12]  R. Vessella,et al.  In vivo Effects of the Human Type I Insulin-Like Growth Factor Receptor Antibody A12 on Androgen-Dependent and Androgen-Independent Xenograft Human Prostate Tumors , 2005, Clinical Cancer Research.

[13]  C. Roberts,et al.  Androgens up-regulate the insulin-like growth factor-I receptor in prostate cancer cells. , 2005, Cancer research.

[14]  B. Groner,et al.  The IGF-1 receptor and its contributions to metastatic tumor growth—novel approaches to the inhibition of IGF-1R function , 2005, Growth factors.

[15]  Robert H. Bell,et al.  Increased Insulin-Like Growth Factor I Receptor Expression and Signaling Are Components of Androgen-Independent Progression in a Lineage-Derived Prostate Cancer Progression Model , 2004, Cancer Research.

[16]  S. Hankinson,et al.  Insulin-like growth factors and neoplasia , 2004, Nature Reviews Cancer.

[17]  Peter Bohlen,et al.  A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand-dependent signaling and inhibits human tumor growth in vivo. , 2003, Cancer research.

[18]  A. Levitzki,et al.  Development of New Insulin-like Growth Factor-1 Receptor Kinase Inhibitors Using Catechol Mimics* , 2003, Journal of Biological Chemistry.

[19]  S. Monti,et al.  Insulin-like growth factor (IGF)-I, IGF-II and IGF type I receptor (IGFR-I) expression in prostatic cancer. , 2003, Anticancer research.

[20]  E. Surmacz,et al.  Role of the IGF‐I receptor in the regulation of cell–cell adhesion: Implications in cancer development and progression , 2003, Journal of cellular physiology.

[21]  C. Mantzoros,et al.  The Role of the IGF System in Cancer: From Basic to Clinical Studies and Clinical Applications , 2002, Oncology.

[22]  Yi Sun,et al.  Insulin-like growth factor receptor-1 as an anti-cancer target: blocking transformation and inducing apoptosis. , 2002, Current cancer drug targets.

[23]  R. Poulsom,et al.  Expression of the type 1 insulin-like growth factor receptor is up-regulated in primary prostate cancer and commonly persists in metastatic disease. , 2002, Cancer research.

[24]  H. Senn,et al.  Insulin-like growth factors and cancer. , 2002, The Lancet. Oncology.

[25]  C. Sawyers,et al.  In vivo progression of LAPC-9 and LNCaP prostate cancer models to androgen independence is associated with increased expression of insulin-like growth factor I (IGF-I) and IGF-I receptor (IGF-IR). , 2001, Cancer research.

[26]  J. Ilan,et al.  Antisense RNA to the type I insulin-like growth factor receptor suppresses tumor growth and prevents invasion by rat prostate cancer cells in vivo. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[27]  L. Chung,et al.  Prostate carcinoma cells that have resided in bone have an upregulated IGF‐I axis , 2004, The Prostate.

[28]  M. Pollak,et al.  Insulin-like growth factors and prostate cancer. , 2001, Epidemiologic reviews.

[29]  M. Motta,et al.  Luteinizing Hormone-Releasing Hormone Agonists Interfere with the Mitogenic Activity of the Insulin-Like Growth Factor System in Androgen-Independent Prostate Cancer Cells* * This work was supported by Associazione Italiana per la Ricerca sul Cancro, Consiglio Nazionale delle Ricerche through the sp , 1999, Endocrinology.